ImmunePrep™ and ChemoPrep™ are designed to optimize the targeted delivery of therapeutic antibodies and cancer chemotherapies. Whereas, ChemoPure™ reflects our vision for diminishing the toxicity of chemotherapy.
Our CompanyThe size of the global market for therapeutic antibodies and cancer chemotherapies in 2022.*
Source
*World Health Organization, Data Bridge Market Research
We created Sigyn Therapy™ to address pathogen-associated inflammatory disorders that are not treatable with drug therapies. Candidate treatment indications include endotoxemia, drug-resistant bacterial and viral infections, community-acquired pneumonia and sepsis.
"We create medical technologies with two attributes in mind: they must offer to overcome a clearly-defined therapeutic limitation and if demonstrated to be effective, would provide a strategic competitive advantage within an established industry."
Jim Joyce
Chairman and CEO Inventor
Stay informed and receive company updates straight to your inbox.
